Abstract Number: VPB0696
Meeting: ISTH 2022 Congress
Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical
Background: Several guidelines specifically suggest how to manage hemophilic patients (PWH) with COVID-19, but recent studies have shown that Covid-19 PWH management does not differ from the general population
Aims: To evaluate our COVID-19 PWH to confirm if this trend is also present in our Centre
Methods: We retrospectively evaluated data about 8 Covid-19 PWH (4 adults and 4 pediatrics) during 2020-22.Median age was 28.7 (range 10-61).5 were hemophilic A (2 severe and 3 moderate), 3 were severe B (one inhibitor). At the moment of observation 6 they had not yet been vaccinated, two had received the second and third doses respectively
Results: Only one 56-year-old patient needed hospitalization: he presented diabetes, hypertension, hepatitis C and prostatic hypertrophy and was admitted to the hospital because of a worsening dyspnea, and was treated with noninvasive ventilation. Heparin was avoided because of the hemorrhagic risk and the other therapies were administered orally or intravenously. He was discharged after 7 days. Of the other adults, a 27-year-old man manifested mild dyspnea and diarrhea without needing hospitalization.The 34-year-old who had received the two doses of vaccine scheduled at that time did not show any symptomatology. The 61-year-old with three doses of vaccine, developed mild symptoms (low grade fever, sore throat, mild muscle pains). All 4 pediatric patients were successfully treated at home:only the inhibitor patient had an episode of nosebleed treated with single by-passant treatment; the pediatric PWH reported mild symptoms: low-grade fever, asthenia, headache, cold and cough; one had a temporary anosmia and ageusia. Results are resumed in table 1
Conclusion(s): Our experience showed no difference between PWH and the general population: the only adult who needed hospitalization was the one with comorbidities and for whom the application of Guidelines for Covid-19 PWH avoided bleedings.The pediatric patients and the vaccinated adults were pauci-symptomatic and were cured at home
Table 1: clinical characteristics of Covid-19 patients with hemophilia
NA: vaccine not available at the time of infection; Complete: full vaccination at that time. No: not vaccinated even though available
To cite this abstract in AMA style:
Sottilotta G, Nicolò G, Mangano C, Luise F, Piromalli A. No difference in the management of Covid-19 hemophilic and non-hemophilic patients [abstract]. https://abstracts.isth.org/abstract/no-difference-in-the-management-of-covid-19-hemophilic-and-non-hemophilic-patients/. Accessed September 22, 2023.« Back to ISTH 2022 Congress
ISTH Congress Abstracts - https://abstracts.isth.org/abstract/no-difference-in-the-management-of-covid-19-hemophilic-and-non-hemophilic-patients/